Discovery of kibdelomycin, a potent new class of bacterial type II topoisomerase inhibitor by chemical-genetic profiling in Staphylococcus aureus.
about
The application of tetracyclineregulated gene expression systems in the validation of novel drug targets in Mycobacterium tuberculosisFlavoenzymes: versatile catalysts in biosynthetic pathwaysOxabicyclooctane-Linked Novel Bacterial Topoisomerase Inhibitors as Broad Spectrum Antibacterial AgentsTarget-based identification of whole-cell active inhibitors of biotin biosynthesis in Mycobacterium tuberculosis.Description of Kibdelosporangium banguiense sp. nov., a novel actinomycete isolated from soil of the forest of Pama, on the plateau of Bangui, Central African Republic.Synthesis and antibacterial activity of monocyclic 3-carboxamide tetramic acidsGyramides prevent bacterial growth by inhibiting DNA gyrase and altering chromosome topology.Thoughts and facts about antibiotics: where we are now and where we are heading.Prescreening bacterial colonies for bioactive molecules with Janus plates, a SBS standard double-faced microbial culturing system.Evolution of antibiotic resistance, catabolic pathways and niche colonization.Chiral bicyclic tetramates as non-planar templates for chemical library synthesis.Synthesis of 3-acyltetramates by side chain manipulation and their antibacterial activity.Mode of action of closthioamide: the first member of the polythioamide class of bacterial DNA gyrase inhibitors.Equisetin, reutericyclin and streptolodygin as natural product lead structures for novel antibiotic libraries.Broadening the spectrum of β-lactam antibiotics through inhibition of signal peptidase type I.Matching the power of high throughput screening to the chemical diversity of natural productsMultitarget ligands in antibacterial research: progress and opportunities.Prospects for new antibiotics: a molecule-centered perspective.The re-emerging role of microbial natural products in antibiotic discovery.Natural products containing 'decalin' motif in microorganisms.Yeast: a microbe with macro-implications to antimicrobial drug discovery.Strategies for target identification of antimicrobial natural products.DNA replication proteins as potential targets for antimicrobials in drug-resistant bacterial pathogens.Kibdelomycin is a potent and selective agent against toxigenic Clostridium difficile.Kibdelomycin is a bactericidal broad-spectrum aerobic antibacterial agentRu-catalyzed sequence for the synthesis of cyclic amido-ethers.Actinomycetes: still a source of novel antibiotics.A chemocentric view of the natural product inventory.Synthesis and Evaluation of N-Phenylpyrrolamides as DNA Gyrase B Inhibitors.Mimics of pramanicin derived from pyroglutamic acid and their antibacterial activity.YM155 inhibits topoisomerase function.Isolation, structure elucidation and antibacterial activity of a new tetramic acid, ascosetin.
P2860
Q26795478-7124A55A-7792-4D95-B634-F3AF0A2DE7ADQ27022878-9E860060-083D-475C-A040-395CC5B33FE9Q27644560-1D7DA52C-6464-403C-AEC5-24675F9F86A3Q30393244-73C29A3A-E659-4489-9F5B-AF0439F55374Q31051790-E7B3A8D4-B70A-4097-ABF0-5A31173A0D1FQ31143275-FBAF9E8C-CDF8-4570-A888-8D359C952552Q33797306-7BFF556A-090C-43DE-BCE8-96313CB6B8ADQ34236332-8A434EED-95AF-466D-B14F-140BE426342CQ34259264-3EABBC6D-A7B5-48BF-B5DB-6CE8976BFB46Q34296018-5FC5AD95-A6A9-413D-958F-8E824D3D2AF8Q34563803-9E59E9DE-50AF-47FE-B9FB-CFBCFCA86575Q35090265-B7A2DBD5-B30F-4D61-A475-B2401FCDB685Q35691408-2DFD0F80-B6B2-4DAB-8FB7-A628EC39310AQ35797301-21154DA0-863E-4032-8F63-69A46364C388Q36172566-9C543495-888F-4A6A-93F9-2C4AC45C4351Q37240957-F9EF70C6-4EBC-45C9-886A-03CBAE7FC776Q38068475-C4F44323-0807-4E05-A64F-2E32E62FD634Q38113689-C792822A-8051-4175-A992-BEDB8274A341Q38219787-6083A9AE-AD57-4EC6-9458-DF38D7608A1EQ38225336-EB63E910-2E69-4A3F-A1AB-A663C9260009Q38601083-6E994216-C29F-45F7-AF9E-0E637FE444D7Q38710256-B1A83323-6C1C-4382-BCAF-F9622B24675FQ39078552-2C2FE46C-0367-4B0C-8EF1-5358752C7767Q39683062-7E438DA8-75DD-4EB3-92E6-BA99177E33B5Q40674704-80E6DCFE-695C-4992-A890-0EA3C3C1A36CQ41823147-E854B44D-270F-4D83-B763-6D593619DFC1Q46319269-4E94A602-3FF4-4160-899B-32B6470F1E3EQ46965285-930F5B7E-EF96-4FEF-8C94-621E627C8823Q48175813-83E0E3B4-06BE-45BC-95AF-5219B77C718EQ48267872-DB443054-1AB8-44FF-87CD-D4EDEBBC6B49Q49218909-E6726B46-F9ED-48CA-A57E-A83BC361BF7BQ50475196-60713AE3-A375-4633-9807-EF54287E5853
P2860
Discovery of kibdelomycin, a potent new class of bacterial type II topoisomerase inhibitor by chemical-genetic profiling in Staphylococcus aureus.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Discovery of kibdelomycin, a p ...... ling in Staphylococcus aureus.
@en
type
label
Discovery of kibdelomycin, a p ...... ling in Staphylococcus aureus.
@en
prefLabel
Discovery of kibdelomycin, a p ...... ling in Staphylococcus aureus.
@en
P2093
P1476
Discovery of kibdelomycin, a p ...... ling in Staphylococcus aureus.
@en
P2093
Deborah L Zink
Francisca Vicente
Janet Sigmund
Jesús Martín
John Allocco
John W Phillips
Jon Polishook
Judyann Wiltsie
Karen Dorso
P304
P356
10.1016/J.CHEMBIOL.2011.06.011
P577
2011-08-01T00:00:00Z